CMV Infection After Letermovir Primary Prophylaxis Discontinuation in Allogeneic Hematopoietic Cell Transplant Recipients

In this single-center study of 61 allogeneic hematopoietic cell transplant (HCT) recipients receiving letermovir primary cytomegalovirus (CMV) prophylaxis for the first 100 days, we report 23% incidence of clinically significant CMV infection during the first 100 days after letermovir discontinuatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Chavaz, Lara, Royston, Léna, Masouridi-Levrat, Stavroula, Mamez, Anne-Claire, Giannotti, Federica, Morin, Sarah, Van Delden, Christian, Chalandon, Yves, Neofytos, Dionysios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10147386/
https://www.ncbi.nlm.nih.gov/pubmed/37125233
http://dx.doi.org/10.1093/ofid/ofad169

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10147386/
https://www.ncbi.nlm.nih.gov/pubmed/37125233
http://dx.doi.org/10.1093/ofid/ofad169

Ejemplares similares